Compare CBL & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBL | DBVT |
|---|---|---|
| Founded | 1978 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1995 | 2014 |
| Metric | CBL | DBVT |
|---|---|---|
| Price | $36.94 | $19.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $45.00 | $31.75 |
| AVG Volume (30 Days) | 116.2K | ★ 235.3K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | ★ 132.09 | N/A |
| EPS | ★ 4.34 | N/A |
| Revenue | ★ $578,373,000.00 | $4,151,000.00 |
| Revenue This Year | N/A | $65.50 |
| Revenue Next Year | N/A | $47.02 |
| P/E Ratio | $8.50 | ★ N/A |
| Revenue Growth | ★ 12.18 | N/A |
| 52 Week Low | $21.10 | $3.91 |
| 52 Week High | $38.97 | $26.19 |
| Indicator | CBL | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 43.78 |
| Support Level | $36.49 | $8.76 |
| Resistance Level | $37.18 | $24.47 |
| Average True Range (ATR) | 0.99 | 1.33 |
| MACD | -0.12 | -0.23 |
| Stochastic Oscillator | 27.68 | 20.04 |
CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.